Chronic kidney disease (CKD) affects several millions of individuals worldwide and despite considerable efforts and research, few therapeutic options remain available. The cannabinoid-1 receptor (CB1R) has emerged as potential targets in both metabolic and non-metabolic CKD due to its pro-fibrotic activity. In parallel, the use of SGLT-2 inhibitors appears to be beneficial for CKD patients. We hypothesize that CB1R blockade combined or not with SGLT2 inhibitors would protect kidneys against the progression of CKD and could represent a novel and powerful therapy against CKD. Thus, we want to demonstrate that CB1R inhibition : 1) provides additional benefits to SGLT2 inhibitors in the treatment of diabetic nephropathies and associated renal fibrosis; 2) reduces renal fibrosis and CKD in a model of non-metabolic renal fibrosis; and 3) check whether CB1R expression could be a marker of renal fibrosis in humans and better establish the optimal therapeutic combination in CKD.